Kenneth E. Sherman

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons

Raymond T. Chung, Janet Andersen, Paul A. Volberding et al. · New England Journal of Medicine · 2004 · 873 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Kenneth E. Sherman, Steven L. Flamm, Nezam H. Afdhal et al. · New England Journal of Medicine · 2011 · 745 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group

Kenneth E. Sherman, Susan D. Rouster, Raymond T. Chung et al. · Clinical Infectious Diseases · 2002 · 732 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12